Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Chinese perspective
Clinical and Molecular Hepatology · 01.04.2023 · 29 (2) · 206-216
DOI: 10.3350/cmh.2022.0402 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical and Molecular Hepatology, erschienen am 01.04.2023. Verfasst von Diyang Xie und 4 weiteren Autor:innen. Beteiligte Einrichtung: Liver Cancer Institute, Zhongshan Hospital, Key Laboratory of Carcinogenesis and Cancer Invasion (Ministry of Education), Fudan University, Shanghai,…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit wurde bisher 182-mal zitiert (Crossref) und nennt 89 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: National Natural Science Foundation of China, Science and Technology Commission of Shanghai Municipality.
Abstract (Originalsprache)
Liver cancer is the fourth most prevalent and the second most lethal cancer in China. Hepatitis B virus (HBV) infection represents a major risk factor for hepatocellular carcinoma (HCC). Liver ultrasonography plus alpha-fetoprotein every 6 months continues to be the predominant surveillance modality. The age-Male-ALBI-Platelets score was recommended in the recent 2022 Chinese guidelines to predict HCC occurrence. The Chinese liver cancer (CNLC) staging system proposed in the 2017 guidelines continues to be the standard model for staging with modifications in the treatment allocations. Considering the aggressive nature of HBV-associated HCC, multimodal and high-intensity strategies like the addition of immunotherapy-based systemic treatment to local therapies, including resection, ablation, and intra-arterial therapies, have been adopted in real-life practices in China. The latest Chinese guidelines recommend atezolizumab plus bevacizumab, suntilimab plus a bevacizumab analog, lenvatinib, sorafenib, donafenib, and FOLFOX (folinic acid, fluorouracil, and oxaliplatin) chemotherapy as first-line treatment without priority. Regorafenib, apatinib, camrelizumab, and tislelizumab have been added as second-line systemic therapies for patients who progressed on sorafenib. Systemic therapies adopted in real-life practice are sophisticated with various combination modalities and different sequences.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Liver Cancer Institute, Zhongshan Hospital, Key Laboratory of Carcinogenesis and Cancer Invasion (Ministry of Education), Fudan University, Shanghai, China.
- Institute of Biomedical Sciences, Fudan University, Shanghai, China.
Förderung
- National Natural Science Foundation of China
- Science and Technology Commission of Shanghai Municipality
Zitieren
APA
Xie, D., Shi, J., Zhou, J., Fan, J., & Gao, Q. (2023). Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Chinese perspective. Clinical and Molecular Hepatology, 29(2), 206-216. https://doi.org/10.3350/cmh.2022.0402
Vancouver
Xie D, Shi J, Zhou J, Fan J, Gao Q. Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Chinese perspective. Clinical and Molecular Hepatology. 2023;29(2):206-216. doi:10.3350/cmh.2022.0402
BibTeX
@article{Xie2023,
author = {Xie, Diyang and Shi, Jieyi and Zhou, Jian and Fan, Jia and Gao, Qiang},
title = {Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Chinese perspective},
journal = {Clinical and Molecular Hepatology},
year = {2023},
volume = {29},
number = {2},
pages = {206--216},
doi = {10.3350/cmh.2022.0402}
}
EUVIMED